Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

sodium zirconium cyclosilicate

- PMLiVE

AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US

- PMLiVE

AstraZeneca’s Enhertu combination approved by FDA for HER2-positive breast cancer

Around one in five breast cancer cases are HER2-positive

- PMLiVE

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

In 2022, nearly one million new patients were diagnosed with gastric cancer

- PMLiVE

AstraZeneca announces $2bn investment in US manufacturing

The new and expanded facilities will support production of rare disease drug treatments

- PMLiVE

AstraZeneca reports positive results from rare disease trial

HES is a group of rare disorders characterised by persistently elevated levels of white blood cells

- PMLiVE

AstraZeneca reports positive results from phase 3 blood pressure trial

The study demonstrated reduction in systolic blood pressure compared to placebo in patient with hypertension

- PMLiVE

Lilly announces plan for new $3bn facility to boost manufacturing in Europe

The facility will be built in the Netherlands and will increase capacity for the company's oral medicines portfolio

- PMLiVE

AstraZeneca to invest $4.5bn in US manufacturing facility

The investment will further support the company’s growing oncology pipeline

- PMLiVE

AstraZeneca announces agreement with US government to reduce medicine costs

The pharma company is the latest to offer direct-to-consumer purchasing

- PMLiVE

EU medicine shortages hit record highs in 2023 and 2024

Even with countermeasures in place, European auditors warn that the risks remain elevated

- PMLiVE

Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

The recommendation for the subcutaneous formulation follows encouraging trial data

- PMLiVE

AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK

Innovative Trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links